JP2021527694A5 - - Google Patents
Info
- Publication number
- JP2021527694A5 JP2021527694A5 JP2020570967A JP2020570967A JP2021527694A5 JP 2021527694 A5 JP2021527694 A5 JP 2021527694A5 JP 2020570967 A JP2020570967 A JP 2020570967A JP 2020570967 A JP2020570967 A JP 2020570967A JP 2021527694 A5 JP2021527694 A5 JP 2021527694A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- inhibitor
- gene encoding
- composition according
- cancer
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076002A JP2024105452A (ja) | 2018-06-21 | 2024-05-08 | 腫瘍溶解性ウイルスを用いた処置 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862687910P | 2018-06-21 | 2018-06-21 | |
| US201862687931P | 2018-06-21 | 2018-06-21 | |
| US201862687920P | 2018-06-21 | 2018-06-21 | |
| US201862687881P | 2018-06-21 | 2018-06-21 | |
| US62/687,920 | 2018-06-21 | ||
| US62/687,931 | 2018-06-21 | ||
| US62/687,881 | 2018-06-21 | ||
| US62/687,910 | 2018-06-21 | ||
| PCT/GB2019/051769 WO2019243847A1 (en) | 2018-06-21 | 2019-06-21 | Treatment using oncolytic virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076002A Division JP2024105452A (ja) | 2018-06-21 | 2024-05-08 | 腫瘍溶解性ウイルスを用いた処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527694A JP2021527694A (ja) | 2021-10-14 |
| JPWO2019243847A5 JPWO2019243847A5 (https=) | 2022-06-24 |
| JP2021527694A5 true JP2021527694A5 (https=) | 2022-06-24 |
Family
ID=67262783
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570967A Pending JP2021527694A (ja) | 2018-06-21 | 2019-06-21 | 腫瘍溶解性ウイルスを用いた処置 |
| JP2024076002A Pending JP2024105452A (ja) | 2018-06-21 | 2024-05-08 | 腫瘍溶解性ウイルスを用いた処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076002A Pending JP2024105452A (ja) | 2018-06-21 | 2024-05-08 | 腫瘍溶解性ウイルスを用いた処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210252135A1 (https=) |
| EP (1) | EP3810191A1 (https=) |
| JP (2) | JP2021527694A (https=) |
| CN (1) | CN112601547A (https=) |
| CA (1) | CA3103371A1 (https=) |
| WO (1) | WO2019243847A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778881A1 (en) | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CA3156880A1 (en) * | 2019-11-06 | 2021-05-14 | Memgen, Inc. | Replication-enhanced oncolytic adenoviruses |
| CN115605586B (zh) * | 2020-04-07 | 2024-09-06 | 深圳市华药康明生物药业有限责任公司 | 工程化溶瘤腺病毒 |
| WO2021235685A1 (ko) * | 2020-05-20 | 2021-11-25 | 바이로큐어 주식회사 | 암 예방 또는 치료용 약학적 조성물 |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| CN113244411B (zh) * | 2021-06-25 | 2021-09-17 | 诺赛联合(北京)生物医学科技有限公司 | 一种基因修饰的溶瘤病毒诱导ctl细胞方法及其在肿瘤治疗的用途 |
| CN113699122B (zh) * | 2021-08-31 | 2023-10-20 | 中国科学院大学宁波华美医院 | 一种多基因融合溶瘤腺病毒及其构建方法和应用 |
| CN114350709A (zh) * | 2021-09-18 | 2022-04-15 | 梁亚龙 | 一种经修饰的溶瘤性腺病毒载体 |
| CN116836283B (zh) * | 2022-05-17 | 2024-05-07 | 苏州万灏生物科技有限公司 | 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用 |
| WO2023226942A1 (zh) * | 2022-05-23 | 2023-11-30 | 上海药明康德新药开发有限公司 | 一种编码免疫刺激因子和抗免疫检查点抗体的重组hsv-1载体 |
| WO2024082263A1 (zh) * | 2022-10-21 | 2024-04-25 | 上海鑫湾生物科技有限公司 | 一种响应缺氧环境控制病毒复制的系统及其用途 |
| CN115976109B (zh) * | 2022-11-07 | 2025-06-27 | 武汉大学 | 一种靶向降解gbp蛋白的hsv-1溶瘤病毒及其制备与应用 |
| CN116555191B (zh) * | 2023-05-26 | 2024-09-17 | 东北农业大学 | 编码白细胞介素24和粒细胞-巨噬细胞集落刺激因子的新城疫病毒在肿瘤治疗中的应用 |
| CN117797263B (zh) * | 2023-11-29 | 2024-06-18 | 华南农业大学 | 一种药物组合物、药物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6092497B2 (ja) | 2006-03-30 | 2017-03-08 | ユニバーシティー オブ カリフォルニア | 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物 |
| WO2011063309A1 (en) * | 2009-11-20 | 2011-05-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| ES2704632T3 (es) * | 2011-09-08 | 2019-03-19 | Univ New York | Virus de herpes simplex oncolítico y sus usos terapéuticos |
| US9789182B2 (en) | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| EP2958592A1 (en) * | 2013-02-22 | 2015-12-30 | F. Hoffmann-La Roche AG | Methods of treating cancer and preventing drug resistance |
| EP3778881A1 (en) * | 2016-01-08 | 2021-02-17 | Replimune Limited | Modified oncolytic virus |
-
2019
- 2019-06-21 US US17/250,205 patent/US20210252135A1/en active Pending
- 2019-06-21 JP JP2020570967A patent/JP2021527694A/ja active Pending
- 2019-06-21 CN CN201980047200.3A patent/CN112601547A/zh active Pending
- 2019-06-21 CA CA3103371A patent/CA3103371A1/en active Pending
- 2019-06-21 WO PCT/GB2019/051769 patent/WO2019243847A1/en not_active Ceased
- 2019-06-21 EP EP19739688.0A patent/EP3810191A1/en active Pending
-
2024
- 2024-05-08 JP JP2024076002A patent/JP2024105452A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527694A5 (https=) | ||
| US12458696B2 (en) | Modified oncolytic virus | |
| JP7146852B2 (ja) | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ | |
| JP2019500909A5 (https=) | ||
| JP2020503871A5 (https=) | ||
| JP2024095709A5 (https=) | ||
| JP2019501670A5 (https=) | ||
| JP2019501671A5 (https=) | ||
| JP2021518408A5 (https=) | ||
| JPWO2019243847A5 (https=) | ||
| HK40045432A (en) | Modified oncolytic virus | |
| HK1257224B (en) | Modified oncolytic virus | |
| HK1257480B (en) | Engineered virus |